Skip to content

9%

DRUG14 trials

Sponsors

Seelos Therapeutics Inc., Eagle Pharmaceuticals Inc., ASST Grande Ospedale Metropolitano Niguarda, Universite De Liege, CHU De Liege, Assistance Publique Hopitaux De Paris

Conditions

Acute Myocardial InfarctionAdult Patients kidney transplant recipients who have developed chronic humoral rejectionBurn injuryCOVID-19 and fluDisorder of ConsciousnessMajor Depression DisordersOpioid use disorderRecovery following elective minimally invasive colorectal surgery

Phase 1

Phase 2

A DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED TRIAL TO ASSESS SAFETY AND EFFICACY OF SLS-005 (TREHALOSE INJECTION, 90.5 MG/ML FOR INTRAVENOUS INFUSION) FOR THE TREATMENT OF ADULTS WITH SPINOCEREBELLAR ATAXIA
CompletedCTIS2022-501004-10-00
Seelos Therapeutics Inc.Spinocerebellar Ataxia type-3 (SCA3)
Start: 2023-01-30End: 2024-02-12Target: 58Updated: 2023-03-10
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CAL02 ADMINISTERED INTRAVENOUSLY IN ADDITION TO STANDARD OF CARE IN SUBJECTS WITH SEVERE COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA (SCABP)
SuspendedCTIS2022-502049-91-00
Eagle Pharmaceuticals Inc.SEVERE COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA (SCABP)
Start: 2023-09-26Target: 81Updated: 2025-09-24
Treating severe brain-injured patients with apomorphine : a behavioural and neuroimaging study
RecruitingCTIS2023-504631-40-01
Universite De Liege, CHU De LiegeDisorder of Consciousness, severe brain injury
Start: 2018-09-05Target: 102Updated: 2025-07-24
CONCOMITANT ADMINISTRATION OF LICENSED VACCINES AGAINST COVID-19 AND FLU WITH OR WITHOUT MF59 ADJUVANT: A MULTI-CENTRE, RANDOMIZED, SINGLE-BLIND CLINICAL TRIAL TO ASSESS IMMUNOGENICITY IN ADULTS AGED 65 AND OVER
CompletedCTIS2024-514798-23-00
Cr2o B.V.COVID-19 and flu
Start: 2024-10-02End: 2025-03-04Target: 120Updated: 2024-10-14
SCARR : « Allogenic Umbilical Cord Mesenchymal Stromal Cells for the treatment of chronic renal (cABMR) graft rejection »
Not yet recruitingCTIS2023-506598-36-00
Assistance Publique Hopitaux De ParisAdult Patients kidney transplant recipients who have developed chronic humoral rejection, diagnosed through a kidney biopsy (Banff 2017 Classification), resistant to conventional treatment (3 injections at one-month intervals of 2g/kg of IVIG)
Target: 22Updated: 2025-08-01
A Randomized, Single-Blind, Fixed-Order Crossover Study to Assess the Effects of CSX-1004 Injection on Fentanyl-Induced Respiratory Depression in Healthy Adult Subjects and Subjects with Opioid Use Disorder
Not yet recruitingCTIS2025-524133-33-00
Cessation Therapeutics Inc.Opioid use disorder
Target: 24Updated: 2026-03-20

Phase 3

Continuous Wound Infiltration versus placebo following elective minimally invasive colorectal surgery; a double-blinded, randomised, placebo-controlled, low-intervention trial (CIMICS trial)
RecruitingCTIS2024-512107-39-00
Catharina Ziekenhuis StichtingRecovery following elective minimally invasive colorectal surgery
Start: 2024-10-30Target: 192Updated: 2024-07-11
Single blind randomized controlled trial to assess the safety and efficacy of high dose pulse intravenous corticosteroid therapy to treat patients with complicated/fulminant acute myocarditis
Not yet recruitingCTIS2023-504169-22-02
ASST Grande Ospedale Metropolitano NiguardaSevere cardiac inflammation
Target: 120Updated: 2025-05-12
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-center Study to Compare the Anti-Depressive Efficacy and Safety of Samyr® IM versus Placebo IM as an Enhancer Adjunctive to Antidepressant Treatment in Major Depression Disorder Patients Who have not Experienced Sufficient Symptoms Improvement Despite Antidepressant Treatment
RecruitingCTIS2024-513022-29-00
Mylan Inc.Major Depression Disorders
Start: 2019-01-09Target: 468Updated: 2026-01-20
The effect of phoSPHocreatine on mEdical emergency team (met) tREated patients: a randomized clinical trial protocol – SPHERE
Not yet recruitingCTIS2024-518474-14-00
Ospedale San Raffaele S.r.l.bradypnea, fall in Glasgow Coma Scale of > 2 points, pulse rate < 40 or > 140 bpm +6
Target: 350Updated: 2025-10-15
MAMI Use of the Methoxyflurane as pain-killer in the prehospital management of Acute Myocardial Infarction
WithdrawnCTIS2023-507296-21-00
Assistance Publique Hopitaux De ParisAcute Myocardial Infarction
Target: 700Updated: 2025-06-13
MAMI Use of the Methoxyflurane as pain-killer in the prehospital management of Acute Myocardial Infarction
Not yet recruitingCTIS2025-523349-86-00
Assistance Publique Hopitaux De ParisAcute Myocardial Infarction
Target: 700Updated: 2026-02-02

Phase 4